Structure-specific and individual-dependent metabolization of human milk oligosaccharides in infants: A longitudinal birth cohort study by Gu, F. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-01 and may be subject to
change.
Structure-Specific and Individual-Dependent Metabolization of
Human Milk Oligosaccharides in Infants: A Longitudinal Birth Cohort
Study
Fangjie Gu, Shuang Wang, Roseriet Beijers, Carolina de Weerth, and Henk A. Schols*
Cite This: https://doi.org/10.1021/acs.jafc.0c07484 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: To follow human milk oligosaccharide (HMO) biosynthesis and in vivometabolization, mother milk and infant feces
from 68 mother−infant dyads at 2, 6, and 12 weeks postpartum were analyzed, with 18 major HMOs quantitated. Fucosylated and
neutral core HMO levels in milk were dependent on mothers’ Lewis/Secretor status, whereas most sialylated HMO levels were
independent. Infant fecal excretion of HMOs gradually declined with age, especially for neutral core structures. Although decreasing
in absolute concentrations in milk during lactation, the relative abundance of total fucosylated HMOs increased in both milk and
feces. Mono-fucosylated HMOs were more consumed than those decorated with two fucose moieties. More (α2-3)-sialylated
HMOs were degraded than (α2-6)-sialylated HMOs. The transition speed of HMO metabolization from nonspecific or structure-
specific consumption stage to the complete consumption stage was individual-dependent. Variation was associated with mode and
place of delivery, where caesarean section or early exposure to hospital environment delayed the transition.
KEYWORDS: consumption pattern, delivery mode, Lewis, Secretor, prebiotics
■ INTRODUCTION
Human milk oligosaccharides (HMOs) have gained increasing
research interest due to their high abundance in human milk
(5−15 g/L),1 as well as the health benefits for infants’ immune
system,2 gut microbiota establishment,3 and cognitive develop-
ment.4,5 After ingestion by infants, HMOs are minimally
digested in the upper gastrointestinal (GI) tract (<5%),6,7 or
absorbed through the brush border into the circulation system
and excreted into urine (0.5−2%).8,9 Instead, HMOs are
mainly utilized by intestinal bacteria as fermentation substrate,
with the remaining HMOs, if any, excreted into the feces.10,11
Colonization of the infant’s intestine by microorganisms
initiates at delivery or already in utero12,13 and follows a
stage-specific development.14 Bifidobacterium species are
known to be predominant in breast-fed infants’ colon, partially
attributed to their HMO assimilation abilities.15,16 Despite
interindividual differences, gut microbiota composition pro-
gresses toward adult-like patterns in the first 3 years of life with
microbial richness and diversity being highly increased.14 A
healthy gut microbiota in early life is vital for maintaining
normal functions of both metabolic and immune systems, both
having a persisting long-term influence.17 Several factors have
been reported as driving force to shape the gut microbiota of
infants, and these include mode of delivery, antibiotic
exposure, premature birth, and feeding method.18,19 Infants
who are exclusively breast-fed, formula-fed, or mixed-fed
showed different transitions across developmental stages.13
HMOs are a group of complex glycans comprising over 240
reported structures, all built from the five monosaccharides
glucose, galactose, N-acetylglucosamine, fucose (Fuc), and N-
acetylneuraminic acid (Neu5Ac).20−23 The core structures of
HMOs start with lactose, extended at the nonreducing end
with one or more specific disaccharides, i.e., lacto-N-biose or
N-acetyllactosamine, in a linear or a branched manner.1
Fucosylated HMOs or sialylated HMOs are formed when
fucose (Fuc) or N-acetylneuraminic acid (Neu5Ac; also
referred to as sialic acid) residues are covalently bound to
the core structures, respectively. HMOs can be further grouped
depending on the number and linkage types of these fucose/
sialic acid moieties, e.g., Fuc-(α1-2)- or (α1-3)- or (α1-4)-
substituted HMO groups, mono- vs di-fucosylated HMOs, or
Neu5Ac(α2-3) vs (α2-6)-substituted HMOs. Composition
and amounts of HMOs secreted into the milk by women are
influenced by maternal genetics and lactation duration.
Considerable amounts of Fuc-(α1-2) and Fuc-(α1-3/4)
structures are secreted by mothers with an active Secretor
(Se)− and Lewis (Le)− gene, respectively.24 When mothers
are non-Secretors, or Lewis-negative, Fuc-(α1-2) and Fuc-(α1-
3/4) structures are nearly absent in their milks, respectively.
HMOs with different structural elements showed distinct
temporal changes regarding concentrations in human milk with
lactation duration.25
Previous studies showed that specific HMO structures
undergo different metabolic fates in the GI tract.26,27
Coincident with the temporal development of infant gut
microbiota, metabolization of HMOs follows a three-stage
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pattern, as proposed by Albrecht et al. based on fecal HMO
profiles at several time points.28 Infant feces in the first weeks
postpartum still contained either neutral HMOs or sialylated
ones. This was followed by a transition to HMO-derived
metabolites, and finally to the absence of any HMO-related
structure with the introduction of solid foods over 6 months of
age.28 However, contradictory findings or exceptional cases
have been reported. Where Chaturvedi et al. found that HMO
patterns in infant feces highly resembled that in mother milk,29
Dotz et al. reported on an infant showing higher abundances of
fecal neutral HMOs at 7 months postpartum compared to that
at 2 months.30 Furthermore, we recognized three distinct
HMO consumption patterns already at 1 month postpartum in
another birth cohort that were (1) complete consumption, (2)
considerable consumption on specific structures, and (3) low
consumption.27 However, these studies have in common that
they were limited by either small sample sizes, single time
points, or did not analytically differentiate between structural
isomers.
To further investigate HMO metabolization by infant gut
microbiota in a longitudinal manner, human milk and paired
infant fecal samples from a longitudinal birth cohort study
collected at 2, 6, and 12 weeks postpartum were analyzed, with
18 major HMOs quantitated. Temporal changes of HMO
profiles in human milk were examined, as well as
metabolization of different structural HMO groups during
the first 12 weeks of life. Progresses of HMO consumption
patterns were compared among infants, to find out possible
factors that influence these different transitional stages.
■ MATERIALS AND METHODS
Birth Cohort and Sample Collection. The study design of the
BINGO study has been published before,31,32 where BINGO stands
(in Dutch) for Biological Influences on Baby’s Health and
Development. The study recruited participants in the Nijmegen−
Arnhem region in the Netherlands with the aim to identify prenatal
and early postnatal factors that predict infant health and development.
The ethical committee of the Faculty of Social Sciences of the
Radboud University approved the study [ECSW2014-1003-189], and
informed consent was signed by participants. In general, healthy
mothers and infants who were delivered >37 weeks of gestational age
were eligible participants, with more detailed initial and postnatal
inclusion criteria described elsewhere.31,32 The infants included in the
current study were born between December 2014 and November
2016. Human milk and infant fecal samples were collected when each
infant reached 2, 6, and 12 weeks of age. Collection of milk samples
from the breast into sterile cups was performed by mothers with hand
expression before the first morning feeding. Infant feces were
collected within 48 h after milk collection, being transited from
diapers into sterile stool vials. These samples were temporarily stored
in the participants’ home freezers until the samples from all three time
points had been collected. At the end of this collection period (i.e.,
after 12 weeks postpartum), the samples were transferred to a −80 °C
laboratory freezer until further HMO analysis. More details about
sample collection procedures can be found in a previous article.33 In
total, 186 human milk samples and 187 infant fecal samples were
received from 75 mother−infant dyads. Thirteen fecal samples
corresponding to five mother−infant pairs were excluded from further
analysis because the infants were formula-fed at all three time points,
without any breast milk samples collected. Six milk samples and four
fecal samples from two pairs were excluded because the gestational
age at birth was not provided. Eighteen fecal samples from nine
infants were excluded due to either unknown feeding type or
mislabeling. The remaining 180 milk samples and 152 fecal samples
were analyzed for HMO concentrations.
HMO Quantitation. HMO concentrations of the milk and fecal
samples were quantitated based on the method as described by Gu et
al. with some adaptations.27 Briefly, milk samples were diluted
twofold, followed by centrifugation at 4 °C (21 000g, 20 min) to
remove the fat layer. Subsequently, a solid-phase extraction (SPE)
procedure was applied to extract oligosaccharides, using Supelclean
ENVI-Carb 250 mg/3 mL cartridges (Sigma-Aldrich; St. Louis, MO).
Two fractions were lyophilized and rehydrated for further analysis: the
fraction containing 3-fucosyllactose (3FL) was analyzed by high-
performance anion exchange chromatography-pulsed amperometric
detection (HPAEC-PAD), whereas the other one containing all other
HMOs was analyzed by porous graphitized carbon−liquid chroma-
tography−mass spectrometry (PGC−LC−MS). Reduction of oligo-
saccharides with sodium borohydride overnight, and a following
purification step with SPE was performed before loading samples to
PGC−LC−MS. Thawed fecal samples were weighed and diluted to
100 mg/mL with Milli-Q water, followed by centrifugation. Then, an
aliquot of 100 μL supernatant was taken directly to reduction and
purification steps, and was analyzed by PGC−LC−MS.
An ICS 5000 system (Dionex, Sunnyvale, CA) equipped with a
CarboPac PA-1 column (250 mm × 2 mm ID) and a CarboPac PA
guard column (25 mm × 2 mm ID) was employed for 3FL analysis.
The column temperature was maintained at 20 °C, and the flow rate
was set as 0.3 mL/min. The injection volume was 10 μL. Mobile
phase A was 0.1 M NaOH, and mobile phase B was 1 M NaOAc in
0.1 M NaOH. The elution profile was as follows: 0−10 min, 0−10%
B; 10−10.1 min, 10−100% B; 10.1−15 min, 100% B; 15−15.1 min,
100−0% B; 15.1−30 min, 0% B. The eluted oligosaccharides were
monitored by a pulsed amperometric detector (Dionex).
An Accela ultrahigh-pressure liquid chromatography system
(Thermo Scientific, Waltham, MA) equipped with a Thermo
Hypercarb column (100 × 2.1 mm2, 3 μm particle size) preceded
by a Hypercarb guard column (10 × 2.1 mm2, 3 μm particle size) was
used to analyze HMOs present in the reduced samples. Eluent A was
1% (v/v) acetonitrile (ACN) in water containing 0.1% (v/v) formic
acid; eluent B was ACN containing 0.1% (v/v) formic acid. The
elution profile was as follows: 0−5 min, 3% B; 5−22 min, 3−20% B;
22−32 min, 20−40% B; followed by washing with 100% B for 10 min
and equilibrating with 3% B for 21 min. Temperatures of the column
oven and sample tray were set at 25 or 10 °C, respectively. The
injection volume was 5 μL. The flow rate of the washing step and the
first 10 min of equilibration was 300 μL/min, and that of the rest of
elution was 200 μL/min. The Velos Pro mass spectrometer (Thermo
Scientific) with an electrospray ionization probe was operated in
negative-ion mode over a mass-to-charge ratio (m/z) range of 300−
2000 Da. Chromeleon 7.1 (Dionex) and XCalibur 4.3 (Thermo
Scientific) were used for processing data obtained from HPAEC-PAD
or LC−MS, respectively.
A number of HMOs was identified by comparing retention times
and mass-to-charge ratios (m/z) to commercial standards, including
3-FL, 2′-fucosyllactose (2′FL), lacto-N-fucopentaose I (LNFP I),
lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP
III), lacto-N-fucopentaose V (LNFP V), lacto-N-difucohexaose I
(LNDFH I), difucosyllactose (DFL), lacto-N-tetraose (LNT), lacto-
N-neotetraose (LNnT), lacto-N-hexaose (LNH), lacto-N-neohexaose
(LNnH), 3′-sialyllactose (3′SL), 6′-sialyllactose (6′SL), sialyl-lacto-N-
tetraose a (LST a), sialyl-lacto-N-tetraose b (LST b), and sialyl-lacto-
N-tetraose c (LST c). Calibration curves were constructed for each
HMO for quantitation, based on integrated peak area from PAD or
MS signals. Two structural isomers, LNT and LNnT, were
quantitated together because of co-elution. Beyond the above-
mentioned HMOs, an adjacent peak following LNDFH I with the
same m/z value was identified as lacto-N-difucohexaose II (LNDFH
II), consistent with the literature.22 Quantitation of LNDFH II was
based on the calibration curve of LNDFH I, by assuming a similar
response factor.
Data and Statistical Analysis. The presence or (near) absence
of 2′FL and LNFP I in human milk was used as indicators of a
mother’s Secretor status, whereas LNFP II acted as an indicator of
Lewis blood groups.27 The mothers were assigned to four milk groups
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based on their milk oligosaccharide profiles: milk group 1, Lewis-
positive Secretor (Le+Se+), milk group 2, Lewis-positive non-Secretor
(Le+Se−); milk group 3, Lewis-negative Secretor (Le−Se+); milk
group 4, Lewis-negative non-Secretor (Le−Se−). In the current study,
the total HMO was defined as the sum of the 18 annotated HMOs.
The sum of 2′FL, LNFP I/II/III/V, DFL, LNDFH I/II, and 3FL was
defined as total fucosylated HMOs; the sum of LNT, LNnT, LNH,
and LNnH was defined as total neutral core HMOs; the sum of 3′SL,
6′SL, and LST a/b/c was defined as total sialylated HMOs.
Furthermore, the group of Fuc-(α1-2) structural HMOs included
2′FL, LNFP I, DFL, and LNDFH I; Fuc-(α1-3/4) group included
3FL, LNFP II/III/V, and LNDFH II; mono-Fuc included 2′FL,
LNFP I/II/III/V, and 3FL; di-Fuc included DFL, and LNDFH I/II.
The sialylated Neu5Ac-(α2-3) HMOs contained 3′SL and LST a,
whereas the Neu5Ac-(α2-6) group included 6′SL and LST b/c.
Relative abundances of total fucosylated, neutral core, and total
sialylated HMOs were calculated as the concentrations of each group
divided by the sum of all individual HMO concentrations. Relative
abundances of Fuc-(α1-2), Fuc-(α1-3/4), mono-Fuc, and di-Fuc
structures were calculated as the concentration of each group divided
by the total of fucosylated HMOs. Relative abundances of Neu5Ac-
(α2-3) and Neu5Ac-(α2-6) groups were calculated as the
concentration of each group divided by the total of sialylated HMOs.
To study longitudinal changes of HMO profiles in human milk, all
milk samples were included for statistical analysis (n = 180). With
respect to longitudinal fecal HMO profiles, only fecal samples
collected from the infants who were exclusively breast-fed at that
specific time point were included (n = 115). To compare the relative
abundances of different structural HMO groups between human milk
and infant fecal samples, mother−infant pairs were excluded if total
fecal HMO concentrations were less than 1 μg/mg, considering full
utilization. Continuous variables, including age postpartum, gesta-
tional age, birthweight, HMO absolute concentrations, as well as
relative abundances in milk and feces, were compared between milk
group 1 and milk group 2 with Mann−Whitney tests, or among the
three time points within each milk group with Kruskal−Wallis with
post hoc stepwise multiple comparisons. Pearson’s χ2 test was used to
compare categorical variables, i.e., gender, delivery mode, and delivery
place, between the milk groups. The calculation of averages, standard
deviations (SD), percentages, and the above-mentioned comparisons
was performed with SPSS Statistics version 26 (IBM Corp., Armonk,
NY). The Spearman rank-order correlation coefficients with
associated p-values between individual HMOs in human milk samples
were calculated using scipy.stats.spearmanr, then visualized with
heatmap using matplotlib.pyplolt in Python (version 3.7.7).
Hierarchical cluster analysis (HCA) was performed for milk groups
1 and 2 separately, based on relative compositional changes of each
quantitated HMO between milk and paired fecal samples at all of the
three time points, with only mother−infant pairs that had full sets of
samples included. Initial relative compositional changes were
calculated by subtracting the relative abundance of individual HMO
in milk from the corresponding relative abundance in paired feces and
then dividing by the former value. All of the positive values were
normalized to 0−100%, by defining the initial maximum positive
values in each sample as 100%. When the total HMO concentration in
a fecal sample was below 1 μg/mg, it was considered as complete
degradation, and the relative composition changes of all individual
HMO structures were designated as −100%. The relative composi-
tional changes were visualized as heatmaps, using color scales function
in Microsoft Excel 2019. The influence of maternal−infant variables
on relative HMO compositional changes at each time point and
overall were evaluated by multiple response permutation procedures
(MRPP). HCA and MRPP were conducted in R (version 3.4.0), using
factoextra and vegan packages, respectively. Results were considered
as statistically significant when p-values were less than 0.05, or highly
significant when less than 0.001.
■ RESULTS
Maternal and Infant Characteristics. Among the 68
pairs, human milk samples from 51 mothers (75%) contained
considerable concentrations of 2′FL, LNFP I, and LNFP II,
indicating active Lewis (Le)− and Secretor (Se)− genes,
therefore assigned to milk group 1 (Le+Se+). The peaks of
2′FL and LNFP I in milks of the remaining 17 pairs (25%)
were all found to be (nearly) absent, while LNFP II was
present in considerable levels, based on which these pairs were
assigned to milk group 2 (Le+Se−). Mothers with genotype Se
+Le− or Se−Le− were absent among the pairs. Maternal and
infant characteristics are summarized and compared in Table 1.
There are no significant differences between the two milk
groups, regarding sample collection time points, gestational age
at birth, birthweight, gender, and delivery mode. However,
significantly fewer mothers from milk group 2 (6%) delivered
at home instead of clinic/hospital, compared to that from milk
group 1 (33%). The difference in delivery place should be
taken into consideration when comparing HMO profiles
between the two milk groups, as the exposure to hospital/
clinic surroundings could influence the initial acquisition of
infant gut microbiota.12
Longitudinal Changes of HMO in Human Milk. A total
of 18 major HMOs were quantitated in 180 human milk
samples, the results of which are summarized in Table 2. Based
on their averages, the most abundant HMOs in milk group 1
were 2′FL and LN(n)T, followed by LNFP I and LNDFH I at
week 2; the concentration of 3FL increased to be the second
most abundant after 2′FL at week 12, while the other above-
mentioned HMOs dropped in concentrations. In milk group 2
samples, LN(n)T, 3FL, and LNFP II were the most
predominant HMOs at all three time points, but HMOs
containing (α1-2)-linked fucose residues were hardly detected.
All fucosylated HMOs, except for LNFP III at week 12,
showed highly significant differences in concentrations
between milk samples from group 1 and group 2 at all three
time points. In general, (α1-2)-linked fucosylated HMOs with
or without other fucose residues were present in higher
concentrations in milk group 1, whereas HMOs containing
Table 1. Characteristics of Study Subjects from Milk Group





(n = 17) p-value
age postpartum, day, mean
(SD)
week 2 15 (1)b 15 (2)d 0.169
week 6 43 (1)b 43 (2)c 0.557
week 12 85 (5)b 85 (3)b 0.716
gestational age, week, mean
(SD)
40.1 (1) 40.0 (1)c 0.542
birthweight, g, mean (SD) 3591 (400) 3580 (456)c 0.652
gender, male, n (%) 26 (53)c 10 (59) 0.651
delivery mode, vaginal, n
(%)
46 (90) 15 (88) 0.818
delivery place, home, n
(%)e
17 (33) 1 (6)b 0.024
aData are presented as mean (standard deviation, SD), or number of
subjects (percentages). bOne case with missing value. cTwo cases
with missing values. dThree cases with missing values. eOther places,
including hospital and clinic, are considered as hospital/clinic.
fSignificant p-values (<0.05) are in bold.
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only (α1-3)- and/or (α1-4)-linked fucose residues were higher
in milk group 2. As to the neutral core structures, milk group 1
contained less LN(n)T at weeks 2 and 12, but more LNH at
week 2 and more LNnH along the first 12 weeks compared to
milk group 2. No differences were found in sialylated HMOs
between the two milk groups except for LST c, which was
naturally more abundant in milk group 1 at all of the time
points. Despite lacking (α1-2)-linked structures, total HMO
concentration secreted by milk group 2 mothers was found to
be lower than milk group 1 only at week 2 (5.9 vs 6.7 g/L,
respectively), while becoming comparable at later time points,
though both groups showed decreases with longer lactation
duration. This longitudinal reduction in concentrations was
found for most individual HMOs, with a few exceptions: DFL
remained stable over lactation in milk group 1; LNFP V,
LNDFH II, and 3′SL were almost unchanged over time in both
milk groups; 3FL levels increased over time in both milk
groups yet the increase in milk group 2 was not significant (p =
0.065); LNFP II reduced significantly in milk group 2 samples,
but remained constant in group 1, while LNFP III showed
exactly the opposite results. It should be noted that these
observations over time were based on concentrations in human
milk, instead of the total volume ingested by infants at that
time, which would most likely lead to different conclusions on
total intake, considering the increasing milk consumption
when babies grew up. Borewicz et al. suggested a rather stable
amount of HMO intake during the first 12 weeks postpartum,
with an estimated changing daily intake of human milk over
time.33
To further investigate the relations between individual
HMOs, correlations were calculated between each structure,
involving all of the 180 milk samples, with significant results
visualized as a heatmap in Figure 1. The heatmap clearly
divided fucosylated HMOs into two groups, one group
containing (α1-2)-linked fucose (2′FL, LNFP I, DFL, and
LNDFH I), the other devoid of (α1-2)-linked fucose (3FL,
LNFP II/III/V, and LNDFH II). HMOs were positively
correlated with each other within the same group (r = 0.42−
0.93), whereas negatively correlated with those from the other
group (r = −0.17 to −0.86). LN(n)T showed weak negative
correlation with (α1-2)-fucosylated group (r = −0.30) and
positive correlation with (α1-3/4)-fucosylated group (r =
0.29−0.54); LNH and LNnH showed the opposite correla-
tions with the two fucosylated groups (r = 0.23−0.61, or −0.17
to −0.64, respectively), although also belonging to the same
neutral core group as LN(n)T. These observations were
consistent with their different concentrations detected in milk
samples from milk group 1 and milk group 2. Hardly any
strong correlations appeared for sialylated HMOs and
fucosylated HMOs, except for LST c, which was positively
correlated with LNFP I (r = 0.57) and negatively correlated
with 3FL (r = 0.55), partly due to its higher abundance in milk
group 2 milks. Except 3′SL, which was found to be
independent of all other HMOs, other sialylated structures
were in general positively correlated with core HMOs and
other sialylated HMOs, with the strongest correlations seen
among 6′SL, LST a, and LST c (r = 0.70−0.88), and between
LST b and LN(n)T (r = 0.74).
The 18 annotated HMOs were further grouped depending
on their common structural elements, i.e., fucosylated group,
neutral core group, sialylated group, (α1-2)-fucosylated group,
(α1-3/4)-fucosylated group, mono-fucosylated group, di-
fucosylated group, (α2-3)-sialylated group, and (α2-6)-
sialylated group, with the sum of each structural group
compared between the two milk groups at three time points
(Figure 2). Milk group 1 contained higher total fucosylated
HMOs at weeks 2 and 12 than milk group 2, while milk group
2 contained higher total neutral core structures at week 2 than
milk group 1, but comparable at other time points. Total
concentrations of sialylated HMOs were not influenced by
Secretor status, despite the higher abundance of LST c in milk
group 1 (Table 2). Total core and total sialylated HMOs
Figure 1. Spearman correlation heatmap between individual HMOs in milk during the first 12 weeks, including both milk groups at all time points.
Color represents correlation from −1 (blue) to +1 (red) for cells with significant levels (p < 0.05), or white if not passing the significance threshold.
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decreased with lactation time for both milk groups. Meanwhile,
total fucosylated HMOs only reduced during weeks 2−6 for
milk group 1 and remained unchanged from week 6 to 12, or
kept constant at all time points for milk group 2. Furthermore,
the sums of (α1-3/4)-fucosylated HMOs, mono-fucosylated
HMOs, and di-fucosylated HMOs for milk group 2 all
remained comparable over the course of lactation. Unlike
milk group 2, (α1-2)-fucosylated HMOs decreased while (α1-
3/4)-fucosylated HMOs increased from week 2 to 12; mono-
and di-fucosylated HMOs both dropped from week 2 to 6, but
remained unchanged at the later time point. The two milk
groups showed quite different distribution of fucosyl linkage
types; nevertheless, no differences were found in their total
mono-fucosylated HMO levels. As to di-fucosylated HMOs, a
higher level was found in milk group 1 compared to the other
milk group. Concentrations of (α2-3)- and (α2-6)-sialylated
HMOs were comparable between milk groups, indicating their
independence from Secretor status of mothers. Albeit present
in higher concentrations, (α2-6)-sialylated HMOs decreased
from week 2 to 12 in both milk groups, whereas (α2-3)-
sialylated HMO levels remained stable in milk group 2 and
dropped only from week 2 to 6 in milk group 1.
Longitudinal Changes of HMO in Infant Feces. HMO
quantitation results of 115 infant fecal samples, which were
collected at breast-fed time points, were included to investigate
longitudinal changes of fecal HMO excretion, with results
summarized in Table 3. It should be noted that concentration
values given here were based on wet weight of feces, which
were influenced by varied water contents of these feces. Only
one infant (B119) was reported to have diarrhea problem at 6
weeks postpartum, while the rest of fecal samples were
collected under healthy conditions. Among infants who were
fed with Secretor milk (milk group 1), the most abundant
HMOs in milk, 2′FL, LN(n)T, LNFP I, and LNDFH I, also
accounted for the major part of HMOs present in their feces at
week 2, with LNDFH I present in much higher concentration
than the others. At later time points, fecal concentrations of
3FL, LNFP II/III, and LST b were relatively higher, whereas
LN(n)T and LNFP I levels dropped most significantly;
meanwhile, the LNDFH I level remained to be predominant.
Infants who received non-Secretor milk (milk group 2) showed
high concentrations of 3FL in their feces at all three time
points, followed by LNFP II. These two HMOs were also most
abundant in the corresponding milks. Another high-level
Figure 2. Concentrations of different HMO structural groups in milk samples at three time points from milk group 1 (Le+Se+, blue) or milk group
2 (Le+Se−, red). Box-whisker plots represent minimum, first quartile, median, third quartile, maximum, and outliers. Asterisks below the bars
indicate significant differences (*p < 0.05, **p < 0.001) between the two milk groups at single time point. Different lowercase letters above the bars
indicate significant differences (p < 0.05) from each other time point within the same milk group.
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HMO in the non-Secretor milk, LN(n)T, was present as the
third richest fecal HMO at week 2 (6.48 μg/mg); however, its
average concentration strongly reduced to 0.84 μg/mg at week
6, and to trace amounts (0.06 μg/mg) at week 12. Four other
HMOs, LNFP II, LNFP III, LNDFH II, and LST b, became
the most concentrated ones at weeks 6 and 12. In general,
infant fecal HMO concentrations displayed larger interindi-
vidual variations compared to that of human milk samples. A
regular pattern was observed that included a gradual decrease
in HMO concentrations excreted into the feces, especially of
neutral core structures (LNT, LNnT, LNH, LNnH), despite
their high concentrations in milk. The lower fecal HMO
excretion reflects the development of infant gut microbiota
with increased colonization of HMO-consuming bacteria.33 It
is noted that the relative level of 3FL in milk group 1 feces
increased slightly, although not significantly, from week 2 to
12. This even may indicate some microbial degradation of 3FL,
since one should also consider the rising amount of milk 3FL
ingested by the nursing infants.
Fecal concentrations of different HMO structural groups are
shown in Figure S1. Despite high variations, total fucosylated
HMOs were relatively more enriched and present in almost
double the concentration of neutral core and sialylated HMOs.
Furthermore, the longitudinal reduction in neutral core and
sialylated HMOs was much more than that found for total
fucosylated HMOs.
Longitudinal Changes of HMO Metabolization. To
investigate metabolic fates of HMOs within the infant gut, we
first compared the relative abundance of each structural group
between human milk and infant feces at different time points
(Figure 3). Inclusion criteria of data in Figure 3 were: milk
group 1, exclusive breast-feeding, total HMO concentrations
higher than 1 μg/mg in infant feces. Although the total level of
fucosylated HMOs in milk decreased in absolute concen-
trations from week 2 to 6, its relative abundance slightly
increased over lactation (from 65 to 76%). Both the absolute
concentrations and relative abundances of the total neutral
core HMOs (from 19 to 16%) and total sialylated HMOs
(from 16 to 9%) in human milk decreased from week 2 to 12.
Similar trends in their relative abundances were observed in
infant feces, where the total fucosylated structures accounted
for the largest proportion at all three time points, and increased
from 71% at week 2 to 86% at week 12. Also, total sialylated
HMOs and total neutral core HMOs dropped from 20 to 11%,
and from 9 to 3%, respectively, over lactation. Although the
core structures accounted for a higher proportion in milk than
sialylated HMOs, their relative abundances were the opposite
in feces. When comparing the distribution of the above-
mentioned three structural groups, fecal HMO profiles showed
relatively more fucosylated structures, less neutral core, and
comparable level of sialylated HMOs than milk at all of the
time points. This difference implies a general utilization
preference by infant gut microbiota, with neutral core HMOs
being the most quickly consumed, followed by sialylated
HMOs, and fucosylated HMOs being the least consumed
during the first 12 weeks of life. Figure 3B shows a rather
comparable distribution for (α1-2)- and (α1-3/4)-fucosylated
HMOs between milk and feces for all time points, which
Figure 3. Relative abundances of different HMO structural groups ((A) total fucosylated, total core, and total sialylated HMO structures; (B) (α1-
2)-fucosylated, and (α1-3)-fucosylated HMO structures; (C) mono-fucosylated, and di-fucosylated HMO structures; (D) (α2-3)-sialylated and
(α2-6)-sialylated HMO structures) in human milk (M) and in paired breast-fed infant feces (F), in which fecal HMOs were not completely utilized
at week 2 (n = 30), week 6 (n = 26), and week 12 (n = 13). All subjects belong to milk group 1. Colored asterisks in (A) below the bars indicate
significant differences (*p < 0.05, **p < 0.001) for the structural groups of the same color, between milk and feces at single time point, while the
black asterisks indicate significant differences for both structural groups in (B)−(D). Different lowercase letters in the bars indicate significant
differences (p < 0.05) from each other time point within the same type of samples (milk, or feces), with each structural group annotated separately
in (A), but both groups annotated by one letter in (B)−(D).
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indicates no preference in microbial consumption of these two
structures in infants fed with Secretor milk. However, the
proportion of (α1-2)-fucosylated HMOs was much higher
than that of (α1-3/4)-fucosylated HMOs at week 2 (∼80 vs
20%), although the abundance of these two groups became
similar at week 12. The comparison between 3-FL and 2′FL in
milk and fecal samples was made separately, and the results are
shown in Figure S2. The utilization of 2′FL at week 2 seemed
higher than that of 3-FL, but the differences were not large
enough to allow general implications. The longitudinal
distribution of mono-fucosylated and di-fucosylated HMOs
remained relatively stable in both milk samples (75−79 vs 25−
21%) and fecal samples (48−65 vs 52−35%), as can be seen in
Figure 3C; however, the lower abundance of mono-fucosylated
HMOs in feces compared to milk indicates that this structural
group was more prone to microbial degradation than di-
fucosylated structures. Within the sialylated HMOs (Figure
3D), (α2-3)-sialylated structures accounted for only 21% of all
sialylated HMOs in milk at week 2, while their proportion
increased with prolonged lactation to 39% at week 12.
Interestingly, their distribution in fecal samples remained
unchanged during all 12 weeks, with around 90% being (α2-
6)-sialylated group, which might be attributed to a growing
assimilating ability of gut microbes toward (α2-3)-sialylated
HMOs with a longer duration of breast-feeding.
Besides the general trend in metabolization of different
HMO groups, we also investigated the temporal HMO
consumption pattern of individual infants, with results
visualized in Figure 4. Only mother−infant pairs that provided
milk and fecal samples from all of the three time points were
included in the evaluation, with milk group 1 and milk group 2
clustered separately. Milk group 1 was divided over two main
clusters (Figure 4A), with cluster A1 not reaching the complete
HMO consumption stage in the first 12 weeks of life, while
cluster A2 showed complete consumption at week 12 the
latest. Cluster A1 was further divided into three subclusters.
Cluster A1-1 (B071, B022, B031, B157, and B122) showed
growing consumption ability toward sialylated HMOs from
week 2 to 12, while the fucosylated HMOs remained the most
abundant in feces. Cluster A1-2 (B020, B015, B021, and B018)
showed especially utilization of the neutral core structures, the
degree of which enhanced with time; meanwhile, fucosylated
and sialylated HMOs were predominantly excreted in feces.
Subcluster A1-3 (B140 and B101) showed a preference for the
consumption of fucosylated HMOs at week 2, but switched to
utilization of neutral core structures at later time points.
Conversely, B039 from the same subcluster A1-3 showed
mainly consumption of sialylated HMOs at week 6 and
changed to a fucosylated HMO consumption pattern at week
12. The other major cluster A2 also contained three
subclusters. In general, subcluster A2-1 (B117, B115, B119,
B118) showed utilization of neutral core structures, 2′FL,
LNFP I, 3FL, and LNFP V at week 2, with 3′SL and LST a
started to be consumed as well from week 6; finally, all HMOs
were consumed at week 12. In contrast, subcluster A2-2 (B045,
B013, B113, B146, B048) showed a stronger ability to degrade
sialylated HMOs than fucosylated HMOs, especially those
containing (α1-3/4)-fucose moieties and at an early lactation
stage. Both subclusters reached complete consumption stage
later than 6 weeks postpartum. Two subjects from subcluster
A2-3 (B104, B08, B091, B007, B130, B069) showed empty
fecal HMO profiles already at 2 weeks postpartum, whereas the
other four subjects from the same subcluster reached the final
stage between weeks 2 and 6. The relative HMO composi-
tional changes of subjects from milk group 2 are shown in
Figure 4B. Interindividual differences were also observed in
Figure 4. Heatmap of relative HMO compositional changes between human milk samples and paired infant feces. The colors range from dark red
to white to dark blue, representing −100% (reduction) to 100% (increment) in feces compared to milk after normalization. Hierarchical clustering
results of the mother−infant pairs are presented in a dendrogram for milk group 1 (A) and milk group 2 (B) separately. Delivery: +, vaginal
delivery; −, caesarean section. Feeding: B/M, breast-feeding/mixed-feeding, with the three successive letters representing feeding type at weeks 2,
6, and 12, respectively. Place: +, hospital/clinic; −, home.
Journal of Agricultural and Food Chemistry pubs.acs.org/JAFC Article
https://doi.org/10.1021/acs.jafc.0c07484
J. Agric. Food Chem. XXXX, XXX, XXX−XXX
I
this group. One subject from milk group 2 reached the
complete consumption stage between week 2 and 6; B067
from milk group 2 could utilize all HMOs at week 12. All other
samples from milk group 2 were not at the final stage of
complete consumption at 12 weeks. All subjects from milk
group 2 were delivered vaginally at hospital/clinic, except one
(B50) that was delivered via caesarean section. There were still
HMOs left in the B050 fecal sample at week 12, especially
sialylated structures, 6′SL, LST c, and LST b. Due to limited
subject numbers, no clear differences were observed between
mother−infant pairs from milk group 1 and milk group 2.
When considering the compositional changes of individual
HMOs, LNT, LNnT, LNH, and LNnH decreased the most at
all of the three time points, followed by 2′FL, LNFP I, LNFP
V, 3′SL, and LST a. The HMOs that showed the strongest
increase in relative compositional levels were LST b and
LNDFH I and LNDFH II. This observation was consistent
with our deduction on preferred degradation of different
structural groups that neutral core, mono-fucosylated, and (α2-
3)-sialylated HMOs were more prone to microbial con-
sumption.
As discussed, quite diverse patterns of HMO metabolization
among these subjects were observed, even within cluster A,
where infants were all fed with Secretor milk. This indicates the
influence of other determinants on HMO metabolization. It is
noted that all of the caesarean-section-born infants belonged to
the main cluster A1, and the infants in A2 were exclusively
vaginally delivered. Furthermore, the occurrence of infants who
were delivered at home was higher in cluster A2 compared to
A1, whereas those delivered at hospital or clinic more likely
clustered into A1. Therefore, multiple response permutation
procedures (MRPP) were performed to identify any possible
differences in HMO consumption clustering that were caused
by maternal−infant variables (Table 4). Both delivery mode
and delivery place had marginally significant influences on the
overall consumption pattern across the 12 weeks. When
considering single time points, the influence of delivery mode
was marginally significant at week 2 and became significant at
week 12. Likewise, delivery place only exerted significant
influence starting from week 6. Although both delivery mode
and place had an effect on the initial acquisition of gut
microbes, their influences on HMO-consuming abilities were
more obvious with the babies’ increasing age. No significant
differences were found between boys and girls, or breast-fed
and mixed-fed infants in the current subset of samples. Due to
the limited samples size, we did not perform MRPP on milk
group 2.
■ DISCUSSION
Longitudinal Changes of HMO in Human Milk. The
longitudinal setup of the Bingo birth cohort study enabled us
to follow the changes in HMO profiles of human milk and
infant fecal samples over the first 12 weeks of age in healthy
Dutch mother−infant pairs. A total of 18 major HMOs were
quantitated in the current study, despite the presence of over
100 structures. However, this is not regarded as a major
problem, as it is generally accepted that more than 90% of total
HMO concentrations in human milk was accounted for by 20
most abundant HMOs.34,35 In the current cohort, 75% of
mothers were assigned to milk group 1 (Le+Se+) and 25% to
milk group 2 (Le+Se−), which was comparable to the range of
distribution as given in the literature (70% Le+Se+ vs 20% Le
+Se−).35−38 The averages of total HMO concentration were
found to be 6.7 and 5.9 g/L in milk from milk groups 1 and 2
at 2 weeks postpartum, respectively, both declined over
lactation to 4.9 and 4.6 g/L at 12 weeks. The concentrations
were in the lower range of that given by widely cited reviews
(5−15 g/L),1,39 although similar concentrations have been
reported (5−8 g/L in mature milk).40,41 Based on our results,
the between-milk group differences were significant at early
lactation stage and disappeared at week 6. It should be noted
that there were no Lewis-negative subjects included in our
study, which might partly explain the slight difference with a
previous finding,41 stating that the total HMO amount were
still higher in Secretor’s milk than non-Secretor at around 5
weeks postpartum.
Although one study pointed out that human milk samples
were predominated by the non-fucosylated HMOs,10 our
samples and another longitudinal study showed the clear
abundancy of fucosylated HMOs in milk,42 with relative levels
continuing to increase over lactation. The synthesis of
fucosylated HMOs in the mammary gland required supply of
both donor substrate nucleotide sugars and acceptor core
structures, like LN(n)T, LN(n)H as well as lactose.42 Due to
competition for substrates, the (near) absence of (α1-2)-
fucosylated HMOs in milk group 2 was compensated by a
higher amount of LN(n)T and (α1-3/4)-fucosylated HMOs,
which was also observed by other studies.42,43 However,
mothers from milk group 1 seemed to produce a higher
amount of LNH and LNnH in the milk compared to those
from milk group 2, although both structures are only present in
the milk at low concentrations. Both Azad et al. and Tonon et
al. also reported higher levels of LNH and/or LNnH in Le+Se
+ milks than those in Le+Se− milks.34,44 The difference in
correlations between LN(n)T or LN(n)H with milk group 1
and milk group 2 implied that the Se gene is only one of the
Table 4. Multiple Response Permutation Procedures
(MRPP) Results to Evaluate Any Differences in HMO
Consumption Clustering of the Study Subjects, as Caused
by the Listed Maternal−Infant Variables, at Each Time
Point and Overallg
time variables Aa p-value
week 2 delivery modeb 0.01831 0.08
delivery placec 0.01032 0.172
infant genderd −0.01302 0.748
feeding typee −0.01345 0.851
week 6 delivery mode 0.01758 0.164
delivery place 0.05845 0.016
infant gender 0.00766 0.293
feeding type −0.01969 0.879
week 12 delivery mode 0.04958 0.042
delivery place 0.05358 0.045
infant gender 0.01589 0.349
feeding type 0.00120 0.351
overall delivery mode 0.01992 0.074
delivery place 0.01904 0.076
infant gender −0.00107 0.497
feeding patternf −0.00080 0.465
aChance corrected within-group agreement A values. bVaginal
delivery vs caesarean section. cHome/clinic vs home. dBoy vs girl.
eBreast-feeding vs mixed-feeding. fBreast-feeding at all time points vs
involvement of mixed-feeding at any time point. gOnly milk group 1
(Le+Se+) samples were included for calculation. Significant p-values
(<0.05) are in bold, and marginally significant p-values (<0.1) are
italicized.
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multiple factors influencing the actual concentrations of these
neutral core HMOs in mother milk. The negative correlations
between (α1-2)- and (α1-3/4)-fucosylated HMOs in milk
group 1 samples were in line with donor− and acceptor−
substrate competition between α1,-2-fucosyltransferase
(FUT2) and α1,-3/4-fucosyltransferase (FUT3), as suggested
by Samuel et al.42 It can be seen from our results that FUT2
had higher activity in early lactation, and FUT3 caught up at a
later stage, which was reflected by the declining concentrations
of 2′FL and LNFP I, while 3FL and LNFP III increased,
confirming earlier literature.25,42,45 The concentration of LFNP
II in milk group 1 remained constant over lactation, which
could be a balance between stronger FUT3 activity and an
overall decreasing synthesis of HMOs in the mammary gland.
Two HMOs that contain (α1-3)-linked fucose moieties at the
reducing-end glucose of base structure LNT, namely, LNFP V
and LNDFH II, kept constant during lactation in both milk
groups, consolidating previous suggestions that their fucosyla-
tion was independent of FUT3 activity.42 The levels of 3′SL,
6′SL, LST, and LST b were not different between milk groups,
except for a higher concentration of LST c in Secretor milk.
Competition for core structures might exist between sialylation
and fucosylation, as found by Samuel et al.,42 although they
concluded that sialylation of LNnT was less influenced by FUT
activities than LNT.42 Nevertheless, the independence of
lactose-derived sialylated structures (3′SL and 6′SL) from
Secretor status was confirmed, as reported in a previous
study.46 As to the temporal changes of 3′SL concentrations in
milk, our study showed stable concentrations in the first 3
months of life, in line with Sprenger et al.46 Note, however,
that Ma et al. found a trend for an increase of 3′SL in Chinese
and Malaysian populations from 2 months to 1 year of age.45
Furthermore, concentrations of 6′SL, LST c, and LST b, which
belonged to the (α2-6)-sialylated HMO group, all declined,
albeit their predominance over (α2-3)-sialylation at 2 weeks
postpartum, in agreement with Austin et al.25
Longitudinal Changes of HMO Metabolization.
HMOs excreted intact in infant feces were those that escaped
from gut microbiota consumption or, to a smaller extent, that
escaped from being absorbed; therefore, by studying the
longitudinal changes of fecal HMO profiles, we could deduce
the metabolic fates of different HMOs in the GI tract, as well
as the development of the gut microbiota of the infants.
Previously, we showed that neutral core structures had the
highest degree of degradation, while fucosylated HMOs had
the lowest, at around 1 month postpartum.27 The same
microbial preferences were confirmed in the current study and,
thanks to the longitudinal design, even found to reach up to 12
weeks postpartum. Despite the generally higher frequency of
2′FL and LNFP I showing lower relative abundances in infant
feces compared to those in the paired human milk (Figure 4),
no differences were found between degradation of (α1-2)- and
(α1-3/4)-fucosylated HMOs at any time point. Di-fucosylated
HMOs were more difficult to be degraded than mono-
fucosylated ones, resulting in higher fecal levels of the former.
HMOs containing (α2-6)-sialic acid were more abundant than
those containing (α2-3)-sialic acid in milk samples, especially
at early stages; however, gut microbes seemed to favor the
latter structural group as fermentation substrates, with their
assimilation abilities even stronger with time. Ingested HMOs
were mostly catabolized by Bif idobacterium, the most
predominant bacteria in early life, with varying abilities to
utilize HMOs among species and strains.15 Already in in vitro
experiments, consumptions of HMOs by Bif idobacteria and
Bacteroides were found to be structure-specific.30 The same
observations have been reported by in vivo studies. LNT and
LNnT, for instance, were two of the most consumed HMOs as
indicated by their lower level or even absence in feces,25,47
similarly to the (α1-2)-fucosylated HMO.26 De Leoz et al. also
found a lower microbial degradation level of LNFP II,
compared to LNFP I/III/V, in the first 13 weeks of age.26
Next to a general trend of consumption of HMO structural
groups, each infant displayed variation in their development
trajectory of consumption patterns from two weeks to 12
weeks. We recognized three consumption patterns among 1-
month-old babies in a previous study,27 including complete
consumption, specific assimilation of core and sialylated
HMOs, or no specific degradation with all HMOs still present
at considerable levels. Taking the three time points of the
present study into consideration, almost all infants showed
growing abilities to degrade HMOs with increased duration of
breast-feeding, with several infants having already developed
the gut microbiota to completely utilize all ingested HMOs at
2 or 6 weeks postpartum. This transition reflected the
development of infant gut microbiota from a non-HMO-
consuming population, acquired from the mothers or
surrounding environment after delivery, toward a population
dominated by HMO-consuming microbes.26 The infant fecal
microbiota compositions of the same set of BINGO samples
were analyzed by Borewicz et al.,33 and a colonization pattern
toward Bif idobacterium-dominated microbial communities in
these infant fecal samples was found. By examining the HMO
metabolization in the current study, we found that the speed of
this above-mentioned transition across developmental stages
was individual-dependent, since almost half of the infants had
not reached the final stage yet at the last time point, 12 weeks
postpartum. This interindividual variation in developmental
trajectories was also noticed in other studies.14,28,30 The
current study found delivery mode to be one factor that
influenced the transition speed, with infants delivered by
caesarean section displaying delayed colonization and enrich-
ment of HMO-consuming microbes compared to those
vaginally delivered, in consistence with the literature.12,19
Besides delivery mode, infants who were delivered at home
tended to show a faster transition to reach the final stage,
compared to those exposed to hospital or clinic environment at
birth. The influence of delivery mode on infant gut microbiota
was also proved by Borewicz et al. based on fecal microbiota of
these same “BINGO” infants; however, no significant differ-
ence between different delivery places were found there.33
Nevertheless, all of these findings indicate the importance of
initial colonization of infant gut for the metabolization of
HMOs. Our results did not find any obvious differences in
HMO metabolization transition between infants fed with
Secretor or non-Secretor milk, although some studies indicated
a negative impact of feeding non-Secretor milk on the gut
development,16 especially those delivered by caesarean
section.43 Furthermore, our results did not find significant
differences in HMO metabolization between breast-fed and
mix-fed infants, although feeding infants with infant formula to
replace human milk is believed to significantly alter infant gut
microbiota.18,48,49 This could be partly due to the exclusion of
entirely formula-fed subjects, and the limited number of mixed-
feeding subjects. Prebiotics, such as galacto- and fructo-
oligosaccharides, supplemented to infant formula nowadays,
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might partially alleviate the negative influence on gut microbial
maturation due to lack of HMOs.13
A limitation of the current study is the lack of Lewis-negative
mothers and their babies, which could have provided more
insights of enzymatic regulation of HMO synthesis as
influenced by FUT3 activity. More subjects from milk group
2 with more variations regarding delivery mode and delivery
place should be included in future studies, to draw solid
conclusions about how these variables possibly affect infant gut
microbiota and fecal HMO profiles. Furthermore, data about
infants’ body growth and development, as well as health status,
should be followed, to find any biological significance of these
differences in HMO consumption development.
To conclude, with more participants and samples from
multiple time points, we were able to follow the temporal
changes of HMO synthesis in mother milk, as well as HMO
metabolization by paired infant gut microbiota, during the first
3 months of life. Lactation duration had a significant influence
on concentrations of individual HMOs in mother milk, as well
as mothers’ Lewis/Secretor status, especially on the fucosylated
and neutral core HMOs, and LST c. The diverse HMO
metabolization patterns by the infant gut microbiota found in
the current study further confirmed the observations of our
previous pilot study and indicated the different stages of gut
microbiota development. The transition of HMO metabo-
lization from a low/nonspecific pattern toward a complete
utilization pattern is individual-dependent and can be partly
attributed to differences in mode and place of delivery.
Although it remains unknown how the gut microbiota
developmental pattern and HMO metabolization stages
would link to long-term health outcomes, more attention is
suggested to be paid on personalized nutrition, to provide
infants with the most appropriate HMOs at specific
developmental stage. Furthermore, HMOs with different
structures were utilized with different preferences by infant
gut microbiota, which could lead researchers and product
developers to identify specific compounds of interest to be
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sialyllactose; 6′SL, 6′-sialyllactose; ACN, acetonitrile;
BINGO, Biological Influences on Baby’s Health and Develop-
ment (in Dutch); DFL, difucosyllactose; Fuc, fucose; FUT2,
α1,-2-fucosyltransferase; FUT3, α1,-3/4-fucosyltransferase; GI,
gastrointestinal; HCA, hierarchical cluster analysis; HMOs,
human milk oligosaccharides; HPAEC-PAD, high-performance
anion exchange chromatography-pulsed amperometric detec-
tion; Le/Se, Lewis/Secretor; LNDFH, lacto-N-difucohexaose;
LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnH,
lacto-N-neohexaose; LNT, lacto-N-tetraose; LST, sialyl-lacto-
N-tetraose; MRPP, multiple response permutation procedures;
m/z, mass-to-charge ratios; Neu5Ac, N-acetylneuraminic acid;
PGC−LC−MS, porous graphitized carbon−liquid chromatog-
raphy−mass spectrometry; SD, standard deviation; SPE, solid-
phase extraction
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